Technology ID
E-016-2013

Diagnostic Assays for the Detection of Thyroid Cancer

Linked ID
NCI-E-016-2013
Inventors
Jeffrey Baron (NICHD)
Youn Jee ()
Lead Inventors
Jeffrey Baron (NICHD)
Co-Inventors
Youn Jee ()
Development Stages
Pre-clinical (in vivo)
Development Status
Pre-clinical (in vivo)
Applications
Diagnostics
ICs
NICHD
Commercial Applications
  • A diagnostic kit for the detection of thyroid cancer.
Thyroid cancer represents a disease particularly amenable to improved methods of diagnosis. Current methods of diagnosis determining the malignancy of thyroid nodules involve needle biopsies and microscopic inspections which are subjective, often leading to inconclusive results and the need for surgery. Therefore, there is a need for improved methods of diagnostic accuracy.NIH scientists have developed two ELISA assays for distinguishing malignant versus benign thyroid biopsy samples. The ELISA assays quantify the amount of midkine and pleiotrophin present in thyroid tissue samples collected from fine needle aspirates. Midkine and pleiotrophin are both low molecular weight growth factors that are over-expressed in many cancerous tissues. Application of this technique for the identification of thyroid cancer represents a first-in-class diagnostic for this disease.
Competitive Advantages

• High assay sensitivity permits the use of small tissue samples (e.g., fine needle aspirates of nodules)

• Assay can incorporate commercially-available midkine or pleiotrophin antibodies.

• Assay relies on proven ELISA detection technology.

Request More Info

Licensing Contact